Long Term Evaluation of Quantitative Cumulative Irradiation in Patients Suffering from ILDs.

CT scan interstitial lung disease irradiation

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
26 Sep 2024
Historique:
received: 27 06 2024
revised: 30 08 2024
accepted: 06 09 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

Interstitial lung diseases (ILDs) are an heterogeneous group of infiltrating lung pathologies, for which prompt diagnosis and continuous assessment are of paramount importance. While chest CT is an established diagnostic tool for ILDs, there are no formal guidelines on the follow-up regimen, leaving the frequency and modality of follow-up largely at the clinician's discretion. The study retrospectively evaluated the indication of chest CT in a cohort of 129 ILD patients selected from the ambulatory care polyclinic at University Hospital of Liège. The aim was to determine whether the imagining acquisition had a true impact on clinical course and follow-up. We accepted three different situations for justifying the indication of the CTs: clinical deterioration, a decrease in pulmonary function tests (at least a 10% drop in a parameter), and monitoring for oncological purposes. The other indications, mainly routine follow-up, were classified as "non-justified". Radiation dose output was evaluated with Computed Tomography Dose Index (CTDI) and Dose Length Product (DLP). The mean number of CT scans per patient per year was 1.7 ± 0.4, determining irradiation in CTDI (mGy)/year of 34.9 ± 64.9 and DLP in (mGy*cm)/year of 1095 ± 1971. The percentage of justified CT scans was 57 ± 32%, while the scans justified a posteriori were 60 ± 34%. Around 40% of the prescribed monitoring CT scans had no impact on the management of ILD and direct patient care. Our study identifies a trend of overuse in chest CT scans at follow-up (up to 40%), outside those performed for clinical exacerbation or oncological investigation. In the particular case of ILD exacerbation, CT scan value remains high, underlying the benefit of this strategy.

Sections du résumé

BACKGROUND BACKGROUND
Interstitial lung diseases (ILDs) are an heterogeneous group of infiltrating lung pathologies, for which prompt diagnosis and continuous assessment are of paramount importance. While chest CT is an established diagnostic tool for ILDs, there are no formal guidelines on the follow-up regimen, leaving the frequency and modality of follow-up largely at the clinician's discretion.
METHODS METHODS
The study retrospectively evaluated the indication of chest CT in a cohort of 129 ILD patients selected from the ambulatory care polyclinic at University Hospital of Liège. The aim was to determine whether the imagining acquisition had a true impact on clinical course and follow-up. We accepted three different situations for justifying the indication of the CTs: clinical deterioration, a decrease in pulmonary function tests (at least a 10% drop in a parameter), and monitoring for oncological purposes. The other indications, mainly routine follow-up, were classified as "non-justified". Radiation dose output was evaluated with Computed Tomography Dose Index (CTDI) and Dose Length Product (DLP).
RESULTS RESULTS
The mean number of CT scans per patient per year was 1.7 ± 0.4, determining irradiation in CTDI (mGy)/year of 34.9 ± 64.9 and DLP in (mGy*cm)/year of 1095 ± 1971. The percentage of justified CT scans was 57 ± 32%, while the scans justified a posteriori were 60 ± 34%. Around 40% of the prescribed monitoring CT scans had no impact on the management of ILD and direct patient care.
CONCLUSIONS CONCLUSIONS
Our study identifies a trend of overuse in chest CT scans at follow-up (up to 40%), outside those performed for clinical exacerbation or oncological investigation. In the particular case of ILD exacerbation, CT scan value remains high, underlying the benefit of this strategy.

Identifiants

pubmed: 39410540
pii: diagnostics14192136
doi: 10.3390/diagnostics14192136
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : European Union
ID : 101096473

Auteurs

Julien Berg (J)

Department of Respiratory Medicine, University Hospital of Liège, 4000 Liège, Belgium.

Anne-Noelle Frix (AN)

Department of Respiratory Medicine, University Hospital of Liège, 4000 Liège, Belgium.

Monique Henket (M)

Department of Respiratory Medicine, University Hospital of Liège, 4000 Liège, Belgium.

Fanny Gester (F)

Department of Respiratory Medicine, University Hospital of Liège, 4000 Liège, Belgium.

Marie Winandy (M)

Department of Respiratory Medicine, University Hospital of Liège, 4000 Liège, Belgium.

Perrine Canivet (P)

Department of Radiology, University Hospital of Liège, 4000 Liège, Belgium.

Makon-Sébastien Njock (MS)

Department of Respiratory Medicine, University Hospital of Liège, 4000 Liège, Belgium.

Marie Thys (M)

Department of Biostatistics and Medico-Economic Information, University Hospital of Liège, 4000 Liège, Belgium.

Colin Desir (C)

Department of Radiology, University Hospital of Liège, 4000 Liège, Belgium.

Paul Meunier (P)

Department of Radiology, University Hospital of Liège, 4000 Liège, Belgium.

Renaud Louis (R)

Department of Respiratory Medicine, University Hospital of Liège, 4000 Liège, Belgium.

Francoise Malchair (F)

Department of Clinical Science, University of Liège, 4000 Liège, Belgium.

Julien Guiot (J)

Department of Respiratory Medicine, University Hospital of Liège, 4000 Liège, Belgium.

Classifications MeSH